全文获取类型
收费全文 | 736篇 |
免费 | 27篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 38篇 |
妇产科学 | 4篇 |
基础医学 | 64篇 |
口腔科学 | 10篇 |
临床医学 | 51篇 |
内科学 | 196篇 |
皮肤病学 | 2篇 |
神经病学 | 12篇 |
特种医学 | 312篇 |
外科学 | 18篇 |
综合类 | 12篇 |
预防医学 | 18篇 |
眼科学 | 3篇 |
药学 | 31篇 |
中国医学 | 1篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 9篇 |
2020年 | 1篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 6篇 |
2012年 | 5篇 |
2011年 | 7篇 |
2010年 | 12篇 |
2009年 | 15篇 |
2008年 | 7篇 |
2007年 | 20篇 |
2006年 | 8篇 |
2005年 | 8篇 |
2004年 | 4篇 |
2003年 | 3篇 |
2002年 | 9篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 14篇 |
1998年 | 47篇 |
1997年 | 39篇 |
1996年 | 58篇 |
1995年 | 43篇 |
1994年 | 34篇 |
1993年 | 38篇 |
1992年 | 9篇 |
1991年 | 10篇 |
1990年 | 10篇 |
1989年 | 32篇 |
1988年 | 35篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 39篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 25篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 26篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1969年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有785条查询结果,搜索用时 0 毫秒
31.
32.
Ionotropic glutamate (Glu) receptors of the N-methyl-D-aspartate type (NMDA) play a fundamental role in many cortical functions. Native NMDA receptors are composed of a heteromeric assembly of different subunits belonging to two classes: NMDAR1 (NR1) and NMDAR2 (NR2). To date, NMDA receptors are believed to be expressed only in neurons, although electrophysiological and in situ hybridization studies have suggested that this class of Glu receptors might be also expressed by some astrocytes. In this study, we have investigated in the cerebral cortex of adult rats the presence of astrocytes expressing NR1 and NR2A/B subunits by immunocytochemistry with specific antibodies, and we show that some distal astrocytic processes, but only rarely astrocytic cell bodies, contain immunoreaction product indicative of NR1 and NR2A/B expression. These findings suggest that at least part of the role NMDA has in cortical functions might depend on the activation of astrocytic NMDA receptors; the subcellular localization of NR1 and NR2A/B subunits in distal processes suggests that NMDA receptors contribute to monitoring Glu levels in the extracellular space. © 1996 Wiley-Liss, Inc. 相似文献
33.
鸟氨酸脱羧酶的生理病理特点及其药物研究概况 总被引:2,自引:0,他引:2
鸟氨酸脱羧酶(ornithinedecarboxylase,ODC)是多胺代谢中的关键酶,广泛存在于人体和动物各组织细胞内,其中对肠细胞的增生、移行和分化起重要作用.机体调节因素比较复杂.在黏膜损伤性疾病及某些癌前病变等细胞大量增生的病理情况下ODC的表达发生改变,可以作为这些疾病分期、预后及药物作用靶点或疗效的指标.寻找对ODC有作用的药物对于治疗其相关疾病是非常有意义的. 相似文献
34.
35.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
36.
37.
38.
39.